Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.42 |
| ▸ | CES1 | P23141 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 6/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764710 | 1.00 | CES2 (0.42) | CES2CES1LMNAHPGDL3MBTL1 | |
| SCHEMBL12018317 | 0.71 | CES2 (0.52) | CES2CES1LMNAHPGDL3MBTL1 | |
| SCHEMBL8827718 | 0.70 | CTSK (0.51) | MAPT | |
| SCHEMBL1764167 | 0.69 | MTOR (0.39) | LMNAHPGDCYP2D6SRCMAPK1 | |
| SCHEMBL7719888 | 0.69 | CTRB1 (0.52) | LMNACYP2D6CTRB1ALDH1A1SMN1; SMN2 | |
| Benzil SCHEMBL11423943 | 0.69 | CES2 (0.78) | CES2CES1LMNAHPGDL3MBTL1 | |
| SCHEMBL9388831 | 0.67 | SMN1; SMN2 (0.47) | CES2CES1LMNAHPGDL3MBTL1 | |
| SCHEMBL14397456 | 0.67 | LMNA (0.54) | CES2CES1LMNAHPGDALDH1A1 | |
| SCHEMBL15275314 | 0.66 | ACP3 (0.51) | LMNACYP2D6MAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9123895 | 0.65 | CES2 (0.62) | CES2CES1HPGDL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2018-11-20 | — | — | US | disclosed |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS (FR) | 2014-06-12 | — | — | US | disclosed |
| US-8703747-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | CES2 1104/4885CES1 1841/4885LMNA 4645/4885 |
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | OPRM1, HRH3, HRH4 | CES2 1040/4885CES1 1812/4885LMNA 4614/4885 |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | CES2 1040/4885CES1 1812/4885LMNA 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.